

DECEMBER 2025

Date	Headline and Source	Link	Summary
1 st December	India's Pharma Growth: Policy Push, Innovation & Global Ambition Clearcut Media Co, December 01, 2025	India's Pharma Growth: Policy Push, Innovation & Global Ambition	According to a report by EY Parthenon and the Organization of Pharmaceutical Producers of India (OPPI) the pharmaceutical industry is key to India's goal of becoming a \$30–35 trillion economy by 2047. The report, Fuelling innovation, advancing equity: The power of partnerships and digital-first strategies driving Indian pharma's global dominance, presents a plan to move the sector away from efficiency driven by cost and toward innovation powered by science.
1 st December	Indian pharmaceutical industry: Transitioning into a global innovation and manufacturing powerhouse Fortune, December 01, 2025	Indian pharmaceutical industry: Transitioning into a global innovation and manufacturing powerhouse	Today, India ranks third globally in pharmaceutical volume and 14th in value, with an industry size of US\$55 billion, including a US\$26 billion domestic market. Pharma exports have risen from US\$15.07 billion in 2013–14 to US\$27.85 billion in FY24, clocking a CAGR of 7%. Exports are expected to cross US\$30 billion this year. Between 2025 and 2047, the sector is projected to surge to US\$450 billion, according to a recent report by the Organisation of Pharmaceutical Producers of India (OPPI) and EYParthenon.
2 nd December	Ministries split on drug data exclusivity The Economic Times, December 02, 2025	Ministries split on drug data exclusivity	According to a submission accessed by ET, the Organisation of Pharmaceutical Producers of India (OPPI), a lobby group comprising multinational pharma companies, has sought a provision of ten year data protection for small molecules and 12 years for biological products.
2 nd December	Comm and Health Ministries Split over Drug Data Exclusivity Norms The Economic Times, December 02, 2025	Comm and Health Ministries Split over Drug Data Exclusivity Norms	According to a submission accessed by ET, the Organisation of Pharmaceutical Producers of India (OPPI), a lobby group comprising multinational pharma companies, has sought a provision of ten-year data protection for small molecules and 12 years for biological products. It stressed that this was in line with its European partners that grants ten-year data protection. "The government is considering a five-year data protection," said a senior industry official.
5 th December	Novo Nordisk gears up for December Ozempic launch in India, sources say	Novo Nordisk gears up for December Ozempic launch in India, sources say	Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three

	The Economic Times, December 05, 2025		sources familiar with the matter said, as it seeks to strengthen its foothold in the world's most populous nation.
5 th December	Novartis expands India development hubs as global pipeline grows Business Today, December 05, 2025	Novartis expands India development hubs as global pipeline grows	Novartis is expanding the work carried out from its India development centres as the Swiss drugmaker amping up its global focus on cardio-renal-metabolic diseases, oncology, immunology and neuroscience. The scale-up comes as the company steps up investments in technology platforms such as radioligand therapy, xRNA, gene and cell therapies, and data-intensive development models.
5 th December	Healthify, Novo Nordisk India Launch AI-Enabled Patient Support Program for Obesity Care Analytics India Mag, December 05, 2025	Healthify, Novo Nordisk India Launch AI-Enabled Patient Support Program for Obesity Care	Novo Nordisk India has partnered with Healthify to launch an AI-driven, dietitian-led Patient Support Program (PSP) designed to support individuals living with obesity through structured lifestyle guidance. The initiative aims to enhance the patient experience, strengthen long-term adherence, and integrate evidence-based lifestyle management alongside obesity medications, including GLP-1 therapies, which have seen a surge in prescription volume in recent years.
10 th December	Safeguards slowing down access to breakthrough drugs in India The Economic Times, December 10, 2025	Safeguards slowing down access to breakthrough drugs in India	Most innovative drugs are not available for low- and middle-income countries (LMICs), a study published in the reputed Journal of American Medical Association (JAMA) said. Director general of the Organisation of Pharmaceutical Producers of India (OPPI) Anil Matai said, regulatory system plays an important role and influences timelines.
12 th December	Securing the Future: Innovation, IP, and India's Road to a Knowledge Economy The Economic Times, December 12, 2025	Securing the Future: Innovation, IP, and India's Road to a Knowledge Economy	With these pillars in place, the country is well-positioned to lead in the 21st century knowledge economy, driving sustainable growth and achieving our prime Minister's vision of making India a global hub of medical self-reliance and innovation. The article is written by Bhushan Akshikar, Vice President and Managing Director, GSK India; President Organisation of Pharmaceutical Producers of India (OPPI).
15 th December	By invitation. Tackling India's future, complex disease burden The Hindu Business Line, December 15, 2025	By invitation. Tackling India's future, complex disease burden	When Maya (name changed), a 42-year-old schoolteacher in Lucknow, collapsed in her classroom from a sudden heart attack, her family was left stunned. She exercised moderately, ate home-cooked meals, and had no obvious risk factors. Streets away, her neighbour's father,

			already in his seventies, found himself battling a strain of tuberculosis that no longer responded to standard medicines. (Organisation of Pharmaceutical Producers of India)
17 th December	Bristol Myers Squibb opens a new AI-powered content hub, Mosaic, in Mumbai PharmaBiz, December 17, 2025	Bristol Myers Squibb opens a new AI-powered content hub, Mosaic, in Mumbai	Bristol Myers Squibb, one of the world's largest biopharmaceutical companies, and Accenture, a global professional services firm, announced the official opening of a new AI-powered content hub, Mosaic, in Mumbai, India.
18 th December	Accenture helps Bristol Myers Squibb to launch AI-based medical content hub Mosaic The Times of India, December 18, 2025	Accenture helps Bristol Myers Squibb to launch AI-based medical content hub Mosaic	Bristol Myers Squibb and Accenture has launched Mosaic, a generative AI-enabled medical content hub in Mumbai, India. The platform will accelerate the pharmaceutical company's commercialisation efforts by identifying physicians educational needs in real-time and enabling rapid creation of patient-centric content.
18 th December	Novartis bets big on India, builds its largest global R&D hub outside Switzerland The Economic Times, December 18, 2025	Novartis bets big on India, builds its largest global R&D hub outside Switzerland	Novartis is deepening its presence in India, positioning the country as one of its most important global centres for biomedical research and drug development outside its headquarters in Basel, Switzerland.
18 th December	Novo Nordisk Gets CDSCO Panel Nod to Conduct India-Specific PMS Studies on Somapacitan Medical Dialogues, December 18, 2025	Novo Nordisk Gets CDSCO Panel Nod to Conduct India-Specific PMS Studies on Somapacitan	At the recent SEC meeting, the expert panel reviewed the proposal presented by Novo Nordisk India to conduct India-specific PMS studies for the approved drug product Somapacitan Injection 5 mg/1.5 ml, 10 mg/1.5 ml and 15 mg/1.5 ml solution for injection in PFP.
18 th December	AstraZeneca Pharma India gets CDSCO nod to import and market datverzo breast cancer drug CNBC TV18, December 18, 2025	AstraZeneca Pharma India gets CDSCO nod to import and market datverzo breast cancer drug	Drug firm AstraZeneca Pharma India Ltd on Wednesday (December 17) said it has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, to import datopotamab deruxtecan powder for concentrate for solution for infusion 100 mg (rDNA origin), marketed under the brand name Datverzo.
19 th December	AstraZeneca Pharma India wins CDSCO permission to import breast cancer drug Datverzo Medical Dialogues, December 19, 2025	AstraZeneca Pharma India wins CDSCO permission to import breast cancer drug Datverzo	Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Government of India to import for sale and distribution of Detumomab Deruxtecan powder for concentrate for solution for infusion 100

			mg (rDNA origin), under Brand name Dataverse, which is a new drug in India.
19 th December	Bristol Myers Squibb, Accenture launch AI powered content hub Mosaic in Mumbai The Economic Times, December 19, 2025	Bristol Myers Squibb, Accenture launch AI powered content hub Mosaic in Mumbai	Mumbai: Bristol Myers Squibb (BMS), in partnership with global professional services firm Accenture, has officially launched an AI powered content hub, Mosaic, in Mumbai, India. Billed as a first of its kind, end to end generative AI enabled content hub, Mosaic is designed to accelerate BMS's commercialization efforts by enhancing its digital capabilities.
19 th December	AstraZeneca Pharma India receives CDSCO approval for oncology drug Datopotamab Deruxtecan Bio Spectrum, December 19, 2025	AstraZeneca Pharma India receives CDSCO approval for oncology drug Datopotamab Deruxtecan	News Potential launch timeline in India will be shared post all necessary approvals are obtained image credit forepeak AstraZeneca Pharma India Ltd. (AZPIL), has announced that the Central Drugs Standard Control Organization (CDSCO) has granted regulatory approval to import, sell, and distribute Detumomab Deruxtecan (Dato DXd) in India.
19 th December	Bristol Myers Squibb Launches Mosaic: Signals a New Era for Tech Accelerated Patient Care APN News, December 19, 2025	Bristol Myers Squibb Launches Mosaic: Signals a New Era for Tech Accelerated Patient Care	Bristol Myers Squibb, one of the world's largest biopharmaceutical companies, and Accenture, a global professional services firm, today announced the official opening of a new AI powered content hub, Mosaic, in Mumbai, India.
19 th December	AstraZeneca Pharma gets CDSCO nod for import and sale of Dataverse in India Business Standard, December 19, 2025	AstraZeneca Pharma gets CDSCO nod for import and sale of Dataverse in India	AstraZeneca Pharma India has received government approval to import, sell, and distribute Detumomab Deruxtecan (brand name Dataverse) in a 100 mg infusion format. This authorization from the Central Drugs Standard Control Organization (CDSCO) marks the introduction of this treatment as a new drug in the Indian market.
19 th December	Novartis Strengthens Indian Operations with Biggest R&D Hub Globally India Pharma Outlook, December 19, 2025	Novartis Strengthens Indian Operations with Biggest R&D Hub Globally	Novartis is also rapidly increasing its business footprint in India making India its biggest global R&D center outside Switzerland. The Swiss firm has a workforce exceeding 9,000 employees in Hyderabad and Mumbai. This is a significant change in the way Novartis develops drugs to the global market in India.
19 th December	AstraZeneca Breast Cancer Drug Approved in India Money Rediff, December 19, 2025	AstraZeneca Breast Cancer Drug Approved in India	AstraZeneca receives CDSCO approval to import & sell Detumomab Deruxtecan for HR positive, HER2negative metastatic breast cancer in India New Delhi, Dec 18 (PTI) AstraZeneca Pharma on Thursday said the Central Drugs Standard Control

			Organization has granted regulatory approval to import, sell, and distribute breast cancer drug Detumomab Deruxtecán in India
19 th December	AstraZeneca s New Hope: Fight Against Breast Cancer in India Devdis Course, December 19, 2025	AstraZeneca s New Hope: Fight Against Breast Cancer in India	AstraZeneca Pharma has achieved another milestone as the Central Drugs Standard Control Organization greenlights the import, sale, and distribution of its breast cancer drug, Detumomab Deruxtecán, in India. This approval marks a significant step in providing patients with advanced treatment options against a rising cancer trend.
23 rd December	Eye on \$500 bn by 2047, pharma steps into 2026 with focus on innovation Business Standard, December 23, 2025	Eye on \$500 bn by 2047, pharma steps into 2026 with focus on innovation	"While external headwinds such as tariff fluctuations and global trade realignments present near-term challenges, they also reinforce the strategic importance of building resilient, high-quality manufacturing ecosystems, OPPI Director General Anil Matai said.
24 th December	India's Pharma Sector Eyes \$500Bn By 2047, Puts Innovation Centre Stage Vohn Etnwork, December 24, 2025	India's Pharma Sector Eyes \$500Bn By 2047, Puts Innovation Centre Stage	The Organisation of Pharmaceutical Producers of India, which represents research based global pharmaceutical companies including Pfizer, GlaxoSmithKline and Boehringer Ingelheim, has underlined the importance of the government's renewed focus on elevating manufacturing standards, strengthening protection of intellectual property as a key enabler for sustained investment in research and innovation, and aligning Indian production with global quality benchmarks.
24 th December	Bristol Myers lines up many launches for India with AI speed The Economic Times, December 24, 2025	Bristol Myers lines up many launches for India with AI speed	Bristol Myers Squibb is positioning India as a key growth engine as the US biopharma major enters one of its most active pipeline phases and looks to reshape pharmaceutical commercialisation harnessing artificial intelligence.
26 th December	Novo Nordisk plans bigger play in rare diseases segment in India Fortune, December 26, 2025	Novo Nordisk plans bigger play in rare diseases segment in India	Danish pharmaceutical multinational Novo Nordisk is expanding its presence in inherited blood disorder treatments (hemoglobinopathies) in India. The company s focus include rare diseases like thalassemia and sickle cell disease, says Ludovic Helfgott, Executive Vice President and Head, Product & Portfolio Strategy, Novo Nordisk.
30 th December	India Pharma 2025: From Generics Strength to Biopharma Acceleration	India Pharma 2025: From Generics Strength to Biopharma Acceleration	As India aspires to become a USD 3035 trillion economy by 2047, the pharmaceutical industry is poised to play

	Pharma India Magazine, December 30, 2025		a critical role in driving economic growth and enhancing public health, according to a recent report by EY Parthenon and the Organisation of Pharmaceutical Producers of India (OPPI)
30 th December	Powering precision healthcare with global innovation Business Connect India, December 30, 2025	Powering precision healthcare with global innovation	Recognising this reality, MrMed, India's largest online speciality pharmacy, has taken a decisive step forward with the launch of its state-of-the-art Bengaluru cold chain hub, alongside a strategic partnership with global healthcare leader Eli Lilly. Together, these developments signal a significant advancement in strengthening India's speciality medicine ecosystem.
